Gini Health Debuts Into Chronic Health Care Management, Launches Diabetes Reversal Program
1.10.2021 12:56:00 EEST | Business Wire | Press release
Gini Health, one of North America's fastest growing health-tech companies, has teamed up with world-class doctors to launch a type 2 diabetes reversal program. Riding on the success of its pilot 12-week diabetes reversal program, conducted with participants from South Asian diaspora, Gini Health today announced that it has debuted into chronic health care management.
Data from Gini Health’s 12 week pilot program provided promising evidence that type 2 diabetes can be reversed by making appropriate lifestyle changes. The results showed that 65% of participants enrolled in Gini Health’s diabetes reversal program achieved below 6.5 HBA1c levels, 4-12% weight loss and 40% participants reduced blood pressure while also witnessing improvements in other biomarkers. The program was also successful in reducing insulin injections and diabetes-specific prescriptions medications for 92% of its participants, in just 12 weeks.
Gini's diabetes program is a doctor-led continuous care program customized for each patient using the latest global research and participant's health data. Gini's care team provides daily coaching and support to participants. Gini health’s mobile app records glucose data from continuous glucose monitoring devices along with data from other devices like weight, activity, sleep, blood pressure and food intake. Gini doctors use this data to adjust patient's diet, lifestyle and medication to get the best results continuously.
Managing diabetes is extremely complex and people with diabetes face a hard task of doing it alone with very few doctor visits in a year. They struggle with monitoring and keeping in control their blood sugar levels with diet and medication and at the same time managing associated conditions like high blood pressure. Therefore making a doctor-led program using data and technology was key for Gini Health, if they were going to serve hundreds of millions of people with diabetes globally.
With their continuous care model, they support patients at every step of their remission journey. Gini’s team has top medical experts, including doctors, researchers, nutritionists and care specialists that help their customers achieve their health goals.
"Globally, there is a big gap in the diabetes care model that can be filled with our approach of bringing evidence based research, and combining technology with best doctors. Our pilot program’s success is a great start to make it available to more people." said Gurjot Narwal, Founder & CEO of Gini Health.
About Gini Health
Gini Health is a Canada based health-tech company that serves customers across North America and Europe. Gini Health has received various awards and accolades for its personalized healthcare approach in preventive health care. Gini was invested by global VCs like TechStars, Rangle, Uken among others. It has grown into a digital healthcare services company with the launch of its first chronic health care management program.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005294/en/
Contact information
Media
Sandeep Samra
ssamra@stackflow.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 14:00:00 EET | Press release
Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 14:00:00 EET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 12:37:00 EET | Press release
Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming from outside Hong Kong. The HKTDC presents the world’s largest one-s
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 12:30:00 EET | Press release
FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integrate FX Spot+ and EBS Market liquidity into their existing FlexFX workflows, accelerating time to market and r
Clearwater Analytics Debuts Transparent Risk Platform for Power and Gas Markets at E-world 20269.2.2026 10:00:00 EET | Press release
At E-world Energy & Water 2026, Clearwater Analytics (NYSE: CWAN) will debut CWAN Power and Gas, new risk management capabilities within Beacon by CWAN designed to end the industry’s reliance on black-box systems. With transparent methodologies and source-code visibility, the platform lets trading teams validate and customize calculations for complex power and gas instruments in real time. Visit Booth #5A118 in Hall 5 for live demonstrations. Renewables growth, liquefied natural gas flows, and shifting macroeconomic conditions are reshaping power markets and increasing both volatility and opportunity. Yet many trading firms remain constrained by legacy risk platforms that limit model visibility, customization, and speed-to-market. CWAN Power and Gas removes those constraints by making every calculation transparent, configurable, and auditable in real time—supporting complex instruments such as structured power derivatives and evolving trading strategies. “The energy transition is creat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
